Month: May 2016

Testing Potency and Efficacy of Inhibitors of P13K, SYK, BTK Activity

Inhibitors of PI3K, SYK and BTK pathways are a large focus for pharmaceutical companies with several small molecule inhibitors currently at different stages of development. Enzymatic assays measuring the direct activity of compounds are limited because they do not provide information about the entire pathway controlled by these kinases. If you are interested in learning
Continue Reading

New Health Canada License for BÜHLMANN fCAL® turbo

BÜHLMANN fCAL® turbo Speed, Quality and Flexibility in Calprotectin Quantification BUHLMANN Diagnostics Corp (BDC), BÜHLMANN Laboratories AG’s North American affiliate is proud to announce that its innovative product, BÜHLMANN fCAL® turbo, has received a Medical Device License from Health Canada and is now commercially available in Canada.  The device was approved as a Class 2
Continue Reading
Sign Up for BUHLMANN Updates!

Enter your email and stay on top of things,